435 related articles for article (PubMed ID: 19081173)
41. MHC Class II alleles in ulcerative colitis-associated colorectal cancer.
Garrity-Park MM; Loftus EV; Sandborn WJ; Bryant SC; Smyrk TC
Gut; 2009 Sep; 58(9):1226-33. PubMed ID: 19251712
[TBL] [Abstract][Full Text] [Related]
42. Revisiting the specificity of the MHC class II transactivator CIITA in vivo.
Otten LA; Leibundgut-Landmann S; Huarte J; Kos-Braun IC; Lavanchy C; Barras E; Borisch B; Steimle V; Acha-Orbea H; Reith W
Eur J Immunol; 2006 Jun; 36(6):1548-58. PubMed ID: 16703565
[TBL] [Abstract][Full Text] [Related]
43. Inhibition of MHC class II gene expression in uveal melanoma cells is due to methylation of the CIITA gene or an upstream activator.
Radosevich M; Jager M; Ono SJ
Exp Mol Pathol; 2007 Feb; 82(1):68-76. PubMed ID: 16650406
[TBL] [Abstract][Full Text] [Related]
44. FOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas.
Brown PJ; Wong KK; Felce SL; Lyne L; Spearman H; Soilleux EJ; Pedersen LM; Møller MB; Green TM; Gascoyne DM; Banham AH
Leukemia; 2016 Mar; 30(3):605-16. PubMed ID: 26500140
[TBL] [Abstract][Full Text] [Related]
45. Pathologic expression of MHC class II is driven by mitogen-activated protein kinases.
Martins I; Deshayes F; Baton F; Forget A; Ciechomska I; Sylla K; Aoudjit F; Charron D; Al-Daccak R; Alcaide-Loridan C
Eur J Immunol; 2007 Mar; 37(3):788-97. PubMed ID: 17304627
[TBL] [Abstract][Full Text] [Related]
46. Apoptosis-independent retinoblastoma protein rescue of HLA class II messenger RNA IFN-gamma inducibility in non-small cell lung carcinoma cells. Lack of surface class II expression associated with a specific defect in HLA-DRA induction.
Lu Y; Boss JM; Hu SX; Xu HJ; Blanck G
J Immunol; 1996 Apr; 156(7):2495-502. PubMed ID: 8786310
[TBL] [Abstract][Full Text] [Related]
47. CIITA enhances HIV-1 attachment to CD4+ T cells leading to enhanced infection and cell depletion.
Porter KA; Kelley LN; Nekorchuk MD; Jones JH; Hahn AB; de Noronha CM; Harton JA; Duus KM
J Immunol; 2010 Dec; 185(11):6480-8. PubMed ID: 21041720
[TBL] [Abstract][Full Text] [Related]
48. Hexim1 sequesters positive transcription elongation factor b from the class II transactivator on MHC class II promoters.
Kohoutek J; Blazek D; Peterlin BM
Proc Natl Acad Sci U S A; 2006 Nov; 103(46):17349-54. PubMed ID: 17088550
[TBL] [Abstract][Full Text] [Related]
49. CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory.
Mortara L; Castellani P; Meazza R; Tosi G; De Lerma Barbaro A; Procopio FA; Comes A; Zardi L; Ferrini S; Accolla RS
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3435-43. PubMed ID: 16740768
[TBL] [Abstract][Full Text] [Related]
50. Regulation of the expression of MHC class I and II by class II transactivator (CIITA) in hematopoietic cells.
Liu A; Takahashi M; Toba K; Zheng Z; Hashimoto S; Nikkuni K; Furukawa T; Koike T; Aizawa Y
Hematol Oncol; 1999 Dec; 17(4):149-60. PubMed ID: 10725870
[TBL] [Abstract][Full Text] [Related]
51. Epithelial human leukocyte antigen-DR expression predicts reduced recurrence rates and prolonged survival in rectal cancer patients.
de Bruin EC; van de Velde CJ; van Krieken JH; Marijnen CA; Medema JP
Clin Cancer Res; 2008 Feb; 14(4):1073-9. PubMed ID: 18281539
[TBL] [Abstract][Full Text] [Related]
52. Three novel mutations of the CIITA gene in MHC class II-deficient patients with a severe immunodeficiency.
Dziembowska M; Fondaneche MC; Vedrenne J; Barbieri G; Wiszniewski W; Picard C; Cant AJ; Steimle V; Charron D; Alca-Loridan C; Fischer A; Lisowska-Grospierre B
Immunogenetics; 2002 Feb; 53(10-11):821-9. PubMed ID: 11862382
[TBL] [Abstract][Full Text] [Related]
53. [Inhibition effect of CIITA anti-sense cDNA on the expression of MHCII molecules of Hela cells].
Guo R; Zou P; Fan HH; Cui L; Cao YL; Zheng B; Gao L; Gao F; Lu HZ
Zhonghua Xue Ye Xue Za Zhi; 2003 Dec; 24(12):636-9. PubMed ID: 14761611
[TBL] [Abstract][Full Text] [Related]
54. Autoimmunity and inflammation are independent of class II transactivator type PIV-dependent class II major histocompatibility complex expression in peripheral tissues during collagen-induced arthritis.
Waldburger JM; Palmer G; Seemayer C; Lamacchia C; Finckh A; Christofilopoulos P; Baeten D; Reith W; Gabay C
Arthritis Rheum; 2011 Nov; 63(11):3354-63. PubMed ID: 21739421
[TBL] [Abstract][Full Text] [Related]
55. Transfection of dendritic cells (DCs) with the CIITA gene: increase in immunostimulatory activity of DCs.
Märten A; Ziske C; Schöttker B; Weineck S; Renoth S; Buttgereit P; Schakowski F; König S; von Rücker A; Allera A; Schroers R; Sauerbruch T; Wittig B; Schmidt-Wolf IG
Cancer Gene Ther; 2001 Mar; 8(3):211-9. PubMed ID: 11332992
[TBL] [Abstract][Full Text] [Related]
56. The relationship between HLA class II polymorphisms and somatic deletions in testicular B cell lymphomas of Dutch patients.
Riemersma SA; Jordanova ES; Haasnoot GW; Drabbels J; Schuuring E; Schreuder GM; Kluin PM
Hum Immunol; 2006; 67(4-5):303-10. PubMed ID: 16720210
[TBL] [Abstract][Full Text] [Related]
57. Collagen and major histocompatibility class II expression in mesenchymal cells from CIITA hypomorphic mice.
Xu Y; McDonald J; Perloff E; Butticè G; Schreiber BM; Smith BD
Mol Immunol; 2007 Mar; 44(7):1709-21. PubMed ID: 16982097
[TBL] [Abstract][Full Text] [Related]
58. Mini-review: Specificity and expression of CIITA, the master regulator of MHC class II genes.
LeibundGut-Landmann S; Waldburger JM; Krawczyk M; Otten LA; Suter T; Fontana A; Acha-Orbea H; Reith W
Eur J Immunol; 2004 Jun; 34(6):1513-25. PubMed ID: 15162420
[TBL] [Abstract][Full Text] [Related]
59. Defective class II transactivator expression in a B lymphoma cell line.
Prod'homme T; Drénou B; De Ruyffelaere C; Barbieri G; Wiszniewski W; Bastard C; Charron D; Alcaide-Loridan C
Leukemia; 2004 Apr; 18(4):832-40. PubMed ID: 14973505
[TBL] [Abstract][Full Text] [Related]
60. Multiple mechanisms generate HLA class I altered phenotypes in laryngeal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21.
Maleno I; López-Nevot MA; Cabrera T; Salinero J; Garrido F
Cancer Immunol Immunother; 2002 Sep; 51(7):389-96. PubMed ID: 12192539
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
